Literature DB >> 14513052

Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study.

J L García1, J M Hernandez, N C Gutiérrez, T Flores, D González, M J Calasanz, J A Martínez-Climent, M A Piris, C Lopéz-Capitán, M B González, M D Odero, J F San Miguel.   

Abstract

Comparative genomic hybridization (CGH) studies have demonstrated a high incidence of chromosomal imbalances in non-Hodgkin's lymphoma. However, the information on the genomic imbalances in Burkitt's Lymphoma (BL) is scanty. Conventional cytogenetics was performed in 34 cases, and long-distance PCR for t(8;14) was performed in 18 cases. A total of 170 changes were present with a median of four changes per case (range 1-22). Gains of chromosomal material (143) were more frequent than amplifications (5) or losses (22). The most frequent aberrations were gains on chromosomes 12q (26%), Xq (22%), 22q (20%), 20q (17%) and 9q (15%). Losses predominantly involved chromosomes 13q (17%) and 4q (9%). High-level amplifications were present in the regions 1q23-31 (three cases), 6p12-p25 and 8p22-p23. Upon comparing BL vs Burkitt's cell leukemia (BCL), the latter had more changes (mean 4.3 +/- 2.2) than BL (mean 2.7 +/- 3.2). In addition, BCL cases showed more frequently gains on 8q, 9q, 14q, 20q, and 20q, 9q, 8q and 14q, as well as losses on 13q and 4q. Concerning outcome, the presence of abnormalities on 1q (ascertained either by cytogenetics or by CGH), and imbalances on 7q (P=0.01) were associated with a short survival.

Entities:  

Mesh:

Year:  2003        PMID: 14513052     DOI: 10.1038/sj.leu.2403080

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  14 in total

1.  Secondary abnormalities involving 1q or 13q and poor outcome in high stage Burkitt leukemia/lymphoma cases with 8q24 rearrangement at diagnosis.

Authors:  Mariana Tavares de Souza; Hasmik Mkrtchyan; Rocio Hassan; Daniela Ribeiro Ney-Garcia; Alice Maria Boulhosa de Azevedo; Elaine Sobral da Costa; Amanda Faria de Figueiredo; Thomas Liehr; Eliana Abdelhay; Maria Luiza Macedo Silva
Journal:  Int J Hematol       Date:  2011-01-05       Impact factor: 2.490

2.  MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas.

Authors:  Gabriella Aquino; Laura Marra; Monica Cantile; Annarosaria De Chiara; Giuseppina Liguori; Maria Pia Curcio; Rocco Sabatino; Giuseppe Pannone; Antonio Pinto; Gerardo Botti; Renato Franco
Journal:  Infect Agent Cancer       Date:  2013-09-30       Impact factor: 2.965

3.  Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis.

Authors:  René Scholtysik; Markus Kreuz; Wolfram Klapper; Birgit Burkhardt; Alfred C Feller; Michael Hummel; Markus Loeffler; Maciej Rosolowski; Carsten Schwaenen; Rainer Spang; Harald Stein; Christoph Thorns; Lorenz Trümper; Inga Vater; Swen Wessendorf; Thorsten Zenz; Reiner Siebert; Ralf Küppers
Journal:  Haematologica       Date:  2010-09-07       Impact factor: 9.941

4.  Molecular Cytogenetic Characterization Identified the Murine B-Cell Lymphoma Cell Line A-20 as a Model for Sporadic Burkitt's Lymphoma.

Authors:  Karolina Guja; Thomas Liehr; Martina Rincic; Nadezda Kosyakova; Shaymaa S Hussein Azawi
Journal:  J Histochem Cytochem       Date:  2017-09-13       Impact factor: 2.479

Review 5.  Intracellular Signaling Pathways Involved in Childhood Acute Lymphoblastic Leukemia; Molecular Targets.

Authors:  Cristian Fabián Layton Tovar; Hugo Mendieta Zerón
Journal:  Indian J Hematol Blood Transfus       Date:  2015-10-20       Impact factor: 0.900

6.  An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961.

Authors:  Marilu Nelson; Sherrie L Perkins; Bhavana J Dave; Peter F Coccia; Julia A Bridge; Elizabeth R Lyden; Nyla A Heerema; Mark A Lones; Lauren Harrison; Mitchell S Cairo; Warren G Sanger
Journal:  Br J Haematol       Date:  2009-11-04       Impact factor: 6.998

7.  Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma.

Authors:  Itziar Salaverria; Andreas Zettl; Silvia Beà; Elena M Hartmann; Sandeep S Dave; George W Wright; Evert-Jan Boerma; Philip M Kluin; German Ott; Wing C Chan; Dennis D Weisenburger; Armando Lopez-Guillermo; Randy D Gascoyne; Jan Delabie; Lisa M Rimsza; Rita M Braziel; Elaine S Jaffe; Louis M Staudt; Hans Konrad Müller-Hermelink; Elias Campo; Andreas Rosenwald
Journal:  Haematologica       Date:  2008-08-12       Impact factor: 9.941

8.  Distal chromosome 1q aberrations and initial response to ibrutinib in central nervous system relapsed mantle cell lymphoma.

Authors:  Marcus Høy Hansen; Karen Juul-Jensen; Oriane Cédile; Stephanie Kavan; Michael Boe Møller; Jacob Haaber; Charlotte Guldborg Nyvold
Journal:  Leuk Res Rep       Date:  2021-06-01

9.  Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.

Authors:  H A Poirel; M S Cairo; N A Heerema; J Swansbury; A Aupérin; E Launay; W G Sanger; P Talley; S L Perkins; M Raphaël; K McCarthy; R Sposto; M Gerrard; A Bernheim; C Patte
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

10.  Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas.

Authors:  Pier Paolo Piccaluga; Mohsen Navari; Giulia De Falco; Maria Raffaella Ambrosio; Stefano Lazzi; Fabio Fuligni; Cristiana Bellan; Maura Rossi; Maria Rosaria Sapienza; Maria Antonella Laginestra; Maryam Etebari; Emily A Rogena; Lynnette Tumwine; Claudio Tripodo; Davide Gibellini; Jessica Consiglio; Carlo M Croce; Stefano A Pileri; Lorenzo Leoncini
Journal:  Oncotarget       Date:  2016-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.